FOXP1 and neoplasm: Specifically, targeting the NAT10‐FOXP1 axis in CCa tumors could not only hamper tumor cell glycolysis but also decrease the infiltration of Treg populations into the TME, synergistically enhancing the efficacy of PD‐L1 blockade and ultimately preventing tumor progression.